Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
16 hedge funds and large institutions have $3.12M invested in Rosetta Genomics Ltd. in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
11% less funds holding
Funds holding: 18 → 16 (-2)
21% less capital invested
Capital invested by funds: $3.97M → $3.12M (-$843K)
34% less call options, than puts
Call options by funds: $207K | Put options by funds: $312K
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$611K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$593K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$209K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$141K |
| 5 |
Morgan Stanley
New York
|
+$25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$318K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$204K |
| 3 |
SIM
Spark Investment Management
New York
|
-$168K |
| 4 |
Millennium Management
New York
|
-$124K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$49.5K |
ROSG Hedge Fund Activity: Q2 2014 in Review
16 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q2 2014, worth a combined $3.12M — down 21% from $3.97M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ROSG and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Wells Fargo, adding an estimated $611K. The largest seller was Jane Street, exiting entirely with an estimated $318K sold.
- 16 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q2 2014, down from 18 in Q1 2014.
- Funds reported $3.12M of Rosetta Genomics Ltd. stock for Q2 2014, down 21% quarter-over-quarter.
- 2 funds opened new Rosetta Genomics Ltd. positions in Q2 2014 and 4 closed out, a net change of -2 holders.
- The largest Rosetta Genomics Ltd. buyer in Q2 2014 was Wells Fargo, an estimated $611K added.
- The largest Rosetta Genomics Ltd. seller in Q2 2014 was Jane Street, an estimated $318K sold.
Based on aggregated 13F filings for Q2 2014.